Blueprint Long Term Debt Total vs Net Invested Capital Analysis
BPMC Stock | USD 97.57 0.95 0.98% |
Blueprint Medicines financial indicator trend analysis is way more than just evaluating Blueprint Medicines Corp prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Blueprint Medicines Corp is a good investment. Please check the relationship between Blueprint Medicines Long Term Debt Total and its Net Invested Capital accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.
Long Term Debt Total vs Net Invested Capital
Long Term Debt Total vs Net Invested Capital Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Blueprint Medicines Corp Long Term Debt Total account and Net Invested Capital. At this time, the significance of the direction appears to have no relationship.
The correlation between Blueprint Medicines' Long Term Debt Total and Net Invested Capital is 0.02. Overlapping area represents the amount of variation of Long Term Debt Total that can explain the historical movement of Net Invested Capital in the same time period over historical financial statements of Blueprint Medicines Corp, assuming nothing else is changed. The correlation between historical values of Blueprint Medicines' Long Term Debt Total and Net Invested Capital is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Long Term Debt Total of Blueprint Medicines Corp are associated (or correlated) with its Net Invested Capital. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Net Invested Capital has no effect on the direction of Long Term Debt Total i.e., Blueprint Medicines' Long Term Debt Total and Net Invested Capital go up and down completely randomly.
Correlation Coefficient | 0.02 |
Relationship Direction | Positive |
Relationship Strength | Insignificant |
Long Term Debt Total
Net Invested Capital
The total amount of capital invested in a company, including both equity and debt, minus any cash or cash equivalents.Most indicators from Blueprint Medicines' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Blueprint Medicines Corp current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. At present, Blueprint Medicines' Tax Provision is projected to increase significantly based on the last few years of reporting. The current year's Sales General And Administrative To Revenue is expected to grow to 1.12, whereas Issuance Of Capital Stock is forecasted to decline to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Interest Expense | 7.4M | 16.8M | 51.6M | 54.2M | Depreciation And Amortization | 12.8M | 20.1M | 11.7M | 7.7M |
Blueprint Medicines fundamental ratios Correlations
Click cells to compare fundamentals
Blueprint Medicines Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Blueprint Medicines fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 707.7M | 1.7B | 1.3B | 1.3B | 1.0B | 784.9M | |
Short Long Term Debt Total | 95.9M | 89.6M | 111.4M | 562.7M | 774.1M | 812.8M | |
Other Current Liab | 88.7M | 98.0M | 113.7M | (295.5M) | 128.0M | 134.4M | |
Total Current Liabilities | 106.5M | 130.8M | 149.8M | 183.2M | 214.9M | 225.7M | |
Total Stockholder Equity | 464.4M | 1.5B | 970.7M | 514.7M | 130.6M | 124.1M | |
Other Liab | 47.7M | 35.8M | 28.4M | 437.0M | 502.5M | 527.6M | |
Property Plant And Equipment Net | 111.1M | 101.7M | 120.9M | 115.2M | 115.7M | 63.4M | |
Current Deferred Revenue | 6.2M | 12.6M | 36.6M | 448.6M | 812K | 771.4K | |
Net Debt | (18.0M) | (595.0M) | (98.5M) | 122.7M | 702.8M | 738.0M | |
Retained Earnings | (945.2M) | (631.4M) | (1.3B) | (1.8B) | (2.3B) | (2.2B) | |
Accounts Payable | 4.8M | 4.4M | 8.3M | 2.7M | 4.7M | 3.9M | |
Cash | 113.9M | 684.6M | 209.9M | 119.7M | 71.3M | 67.7M | |
Non Current Assets Total | 190.9M | 790.6M | 698.2M | 303.3M | 240.9M | 236.9M | |
Non Currrent Assets Other | 15.4M | 11.1M | 19.8M | 26.8M | 30.7M | 32.2M | |
Other Assets | 15.4M | 569.3M | 19.8M | 26.8M | 1.0 | 0.95 | |
Cash And Short Term Investments | 548.0M | 1.5B | 1.0B | 1.1B | 710.6M | 656.9M | |
Common Stock Total Equity | 49K | 58K | 59K | 60K | 69K | 41.4K | |
Common Stock Shares Outstanding | 47.8M | 56.2M | 58.5M | 59.6M | 60.6M | 43.6M | |
Liabilities And Stockholders Equity | 707.7M | 1.7B | 1.3B | 1.3B | 1.0B | 784.9M | |
Non Current Liabilities Total | 136.9M | 117.5M | 131.7M | 652.0M | 703.7M | 738.9M | |
Other Current Assets | 379.4M | 22.0M | 18.1M | 35.0M | 33.4M | 51.4M | |
Other Stockholder Equity | 1.4B | 2.1B | 2.3B | 2.4B | 2.5B | 1.3B | |
Total Liab | 243.3M | 248.3M | 281.5M | 835.2M | 918.6M | 964.6M | |
Property Plant And Equipment Gross | 111.1M | 101.7M | 146.3M | 146.5M | 154.1M | 161.9M | |
Total Current Assets | 516.8M | 927.8M | 554.0M | 1.0B | 808.4M | 548.0M | |
Accumulated Other Comprehensive Income | (2.5M) | (5.2M) | (4.1M) | (10.4M) | (3.5M) | (3.7M) | |
Short Term Debt | 6.8M | 15.9M | 16.2M | 27.4M | 81.4M | 85.5M | |
Common Stock | 49K | 58K | 59K | 60K | 61K | 43.7K | |
Property Plant Equipment | 38.4M | 34.1M | 30.7M | 33.3M | 38.3M | 22.7M | |
Net Tangible Assets | 464.4M | 1.5B | 1.2B | 514.7M | 591.9M | 613.2M | |
Net Receivables | 23.4M | 25.3M | 37.0M | 36.9M | 43.2M | 45.3M | |
Short Term Investments | 369.6M | 187.2M | 267.2M | 825.3M | 639.4M | 346.5M | |
Retained Earnings Total Equity | (945.2M) | (631.4M) | (1.3B) | (1.8B) | (1.6B) | (1.6B) | |
Capital Surpluse | 1.4B | 2.1B | 2.3B | 2.4B | 2.7B | 1.5B | |
Inventory | (434.0M) | 8.6M | 21.8M | 29.7M | 21.2M | 22.3M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Blueprint Medicines Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Blueprint Medicines' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Blueprint Medicines Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Blueprint Medicines Corp Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Blueprint Medicines Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Blueprint Medicines. If investors know Blueprint will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Blueprint Medicines listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.09) | Revenue Per Share 6.986 | Quarterly Revenue Growth 1.266 | Return On Assets (0.15) | Return On Equity (0.50) |
The market value of Blueprint Medicines Corp is measured differently than its book value, which is the value of Blueprint that is recorded on the company's balance sheet. Investors also form their own opinion of Blueprint Medicines' value that differs from its market value or its book value, called intrinsic value, which is Blueprint Medicines' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Blueprint Medicines' market value can be influenced by many factors that don't directly affect Blueprint Medicines' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Blueprint Medicines' value and its price as these two are different measures arrived at by different means. Investors typically determine if Blueprint Medicines is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Blueprint Medicines' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.